The biosimilar hormones market size has grown exponentially in recent years. It will grow from $6.22 billion in 2025 to $7.68 billion in 2026 at a compound annual growth rate (CAGR) of 23.5%. The growth in the historic period can be attributed to rising prevalence of diabetes and hormonal disorders, high cost of branded hormone therapies, increasing aging population, growing awareness of hormone replacement therapies, expansion of hospital and retail pharmacy networks.
The biosimilar hormones market size is expected to see exponential growth in the next few years. It will grow to $18.12 billion in 2030 at a compound annual growth rate (CAGR) of 23.9%. The growth in the forecast period can be attributed to patent expiry of major biologic hormones, increasing regulatory support for biosimilars, growing demand for affordable endocrine treatments, expansion of online pharmacy distribution channels, rising investment in biosimilar R&D. Major trends in the forecast period include rising adoption of biosimilar hormones as cost-effective alternatives, increasing demand for insulin and growth hormone biosimilars, growing acceptance of biosimilar hormone therapies among physicians, expansion of biosimilar use in chronic and lifestyle diseases, improved regulatory pathways supporting biosimilar approvals.
The rising level of healthcare expenditure is expected to drive the growth of the biosimilar hormones market in the coming years. Healthcare expenditure represents the total financial resources allocated by individuals, organizations, or governments toward the prevention, treatment, and management of health conditions. Spending on healthcare continues to increase due to advancements in medical technology, as new diagnostic tools, therapies, and innovative treatments are often associated with higher costs, contributing to greater overall healthcare spending. Higher healthcare expenditure supports the adoption of biosimilar hormones by increasing demand for cost-effective treatment options and improving patient access across healthcare systems. For example, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency overseeing Medicare and Medicaid programs, healthcare spending in the United States rose by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person. As a result, rising healthcare expenditure is contributing to the growth of the biosimilar hormones market.
The increasing prevalence of diabetes is also expected to fuel the growth of the biosimilar hormones market. Diabetes is a chronic condition that affects the body’s ability to convert food into energy. Biosimilar hormones, particularly insulin, provide safe and effective alternatives for diabetes management, offering the potential for lower treatment costs and improved patient accessibility. In addition, biosimilar growth hormone may support diabetes treatment by helping improve blood glucose control in adults with type 1 and type 2 diabetes. For instance, in June 2023, the International Diabetes Federation, a Germany-based umbrella organization representing more than 240 national diabetes associations, reported a significant rise in diabetes prevalence, projecting that 783 million adults aged 20 to 79 will be living with diabetes by 2045. Therefore, the growing prevalence of diabetes is expected to further drive the expansion of the biosimilar hormones market in the future.
Major companies operating in the biosimilar hormones market are developing innovative products, such as Sogroya (somapacitan-beco) injection, to strengthen their market position and improve profitability. Sogroya is a prescription analog of human growth hormone used to treat individuals diagnosed with growth hormone deficiency. For example, in April 2023, Novo Nordisk, a Denmark-based pharmaceutical company, received approval from the US Food and Drug Administration for a new indication for Sogroya to treat children aged 2.5 years and older who experience growth failure due to insufficient endogenous growth hormone secretion. Sogroya is currently the only once-weekly growth hormone therapy approved for use in both pediatric and adult patients. The approval was based on results from the phase 3 REAL4 clinical trial, which demonstrated the therapy’s effectiveness in treating growth hormone deficiency in children.
Major companies operating in the biosimilar hormones market are Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited, Mylan, Sanofi, Sandoz Group AG, LG Life Sciences, Ferring Pharmaceuticals, GC Pharma, Pfizer Inc., Dr. Reddy's Laboratories, Amgen Inc., Eli Lilly and Company, Celltrion Inc., Samsungbioepis Co.Ltd, Merck & Co., Biogen Inc., Boehringer Ingelheim, Alvotech, Cipla Limited, Lupin Ltd., Stada Arzneimittel AG, Torrent Pharmaceuticals, Zydus Cadila, Accord Healthcare, Hetero Drugs, Wockhardt.
North America was the largest region in the biosimilar hormones market in 2025. The regions covered in the biosimilar hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biosimilar hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the biosimilar hormones market by increasing the cost of imported active pharmaceutical ingredients, biologic manufacturing equipment, and cold-chain logistics. Insulin and somatropin biosimilar segments are particularly affected, with North America and Europe facing price pressures due to reliance on international supply chains. These tariffs have increased production and distribution costs but have also encouraged local manufacturing, regional capacity expansion, and development of cost-efficient biosimilar hormone products over the long term.
The biosimilar hormones market research report is one of a series of new reports that provides biosimilar hormones market statistics, including biosimilar hormones industry global market size, regional shares, competitors with a biosimilar hormones market share, detailed biosimilar hormones market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar hormones industry. This biosimilar hormones market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Biosimilar hormones refer to hormone products that are chemically identical to those naturally produced by the human body. The hormones used in these therapies may be the same as those found in conventional hormone treatments and are used to manage conditions in which hormone levels are deficient or imbalanced.
The primary types of biosimilar hormones include teriparatide biosimilars, follitropin alfa biosimilars, insulin biosimilars, somatropin biosimilars, and others. Teriparatide is a recombinant parathyroid hormone (PTH) that resembles a component of human PTH and, when administered regularly, stimulates osteoblast activity more than osteoclast activity, thereby increasing bone mass. These products are used in various applications such as research and biotechnology, diagnostics, biocatalysts, therapeutics, and others, and are distributed through multiple channels including hospital and retail pharmacies, online pharmacies or e-pharmacies, and specialty clinics.
The biosimilar hormones market consists of sales of estrace, estradil, and estring. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The biosimilar hormones market size is expected to see exponential growth in the next few years. It will grow to $18.12 billion in 2030 at a compound annual growth rate (CAGR) of 23.9%. The growth in the forecast period can be attributed to patent expiry of major biologic hormones, increasing regulatory support for biosimilars, growing demand for affordable endocrine treatments, expansion of online pharmacy distribution channels, rising investment in biosimilar R&D. Major trends in the forecast period include rising adoption of biosimilar hormones as cost-effective alternatives, increasing demand for insulin and growth hormone biosimilars, growing acceptance of biosimilar hormone therapies among physicians, expansion of biosimilar use in chronic and lifestyle diseases, improved regulatory pathways supporting biosimilar approvals.
The rising level of healthcare expenditure is expected to drive the growth of the biosimilar hormones market in the coming years. Healthcare expenditure represents the total financial resources allocated by individuals, organizations, or governments toward the prevention, treatment, and management of health conditions. Spending on healthcare continues to increase due to advancements in medical technology, as new diagnostic tools, therapies, and innovative treatments are often associated with higher costs, contributing to greater overall healthcare spending. Higher healthcare expenditure supports the adoption of biosimilar hormones by increasing demand for cost-effective treatment options and improving patient access across healthcare systems. For example, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency overseeing Medicare and Medicaid programs, healthcare spending in the United States rose by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person. As a result, rising healthcare expenditure is contributing to the growth of the biosimilar hormones market.
The increasing prevalence of diabetes is also expected to fuel the growth of the biosimilar hormones market. Diabetes is a chronic condition that affects the body’s ability to convert food into energy. Biosimilar hormones, particularly insulin, provide safe and effective alternatives for diabetes management, offering the potential for lower treatment costs and improved patient accessibility. In addition, biosimilar growth hormone may support diabetes treatment by helping improve blood glucose control in adults with type 1 and type 2 diabetes. For instance, in June 2023, the International Diabetes Federation, a Germany-based umbrella organization representing more than 240 national diabetes associations, reported a significant rise in diabetes prevalence, projecting that 783 million adults aged 20 to 79 will be living with diabetes by 2045. Therefore, the growing prevalence of diabetes is expected to further drive the expansion of the biosimilar hormones market in the future.
Major companies operating in the biosimilar hormones market are developing innovative products, such as Sogroya (somapacitan-beco) injection, to strengthen their market position and improve profitability. Sogroya is a prescription analog of human growth hormone used to treat individuals diagnosed with growth hormone deficiency. For example, in April 2023, Novo Nordisk, a Denmark-based pharmaceutical company, received approval from the US Food and Drug Administration for a new indication for Sogroya to treat children aged 2.5 years and older who experience growth failure due to insufficient endogenous growth hormone secretion. Sogroya is currently the only once-weekly growth hormone therapy approved for use in both pediatric and adult patients. The approval was based on results from the phase 3 REAL4 clinical trial, which demonstrated the therapy’s effectiveness in treating growth hormone deficiency in children.
Major companies operating in the biosimilar hormones market are Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited, Mylan, Sanofi, Sandoz Group AG, LG Life Sciences, Ferring Pharmaceuticals, GC Pharma, Pfizer Inc., Dr. Reddy's Laboratories, Amgen Inc., Eli Lilly and Company, Celltrion Inc., Samsungbioepis Co.Ltd, Merck & Co., Biogen Inc., Boehringer Ingelheim, Alvotech, Cipla Limited, Lupin Ltd., Stada Arzneimittel AG, Torrent Pharmaceuticals, Zydus Cadila, Accord Healthcare, Hetero Drugs, Wockhardt.
North America was the largest region in the biosimilar hormones market in 2025. The regions covered in the biosimilar hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biosimilar hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the biosimilar hormones market by increasing the cost of imported active pharmaceutical ingredients, biologic manufacturing equipment, and cold-chain logistics. Insulin and somatropin biosimilar segments are particularly affected, with North America and Europe facing price pressures due to reliance on international supply chains. These tariffs have increased production and distribution costs but have also encouraged local manufacturing, regional capacity expansion, and development of cost-efficient biosimilar hormone products over the long term.
The biosimilar hormones market research report is one of a series of new reports that provides biosimilar hormones market statistics, including biosimilar hormones industry global market size, regional shares, competitors with a biosimilar hormones market share, detailed biosimilar hormones market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar hormones industry. This biosimilar hormones market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Biosimilar hormones refer to hormone products that are chemically identical to those naturally produced by the human body. The hormones used in these therapies may be the same as those found in conventional hormone treatments and are used to manage conditions in which hormone levels are deficient or imbalanced.
The primary types of biosimilar hormones include teriparatide biosimilars, follitropin alfa biosimilars, insulin biosimilars, somatropin biosimilars, and others. Teriparatide is a recombinant parathyroid hormone (PTH) that resembles a component of human PTH and, when administered regularly, stimulates osteoblast activity more than osteoclast activity, thereby increasing bone mass. These products are used in various applications such as research and biotechnology, diagnostics, biocatalysts, therapeutics, and others, and are distributed through multiple channels including hospital and retail pharmacies, online pharmacies or e-pharmacies, and specialty clinics.
The biosimilar hormones market consists of sales of estrace, estradil, and estring. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Biosimilar Hormones Market Characteristics
3. Biosimilar Hormones Market Supply Chain Analysis
4. Global Biosimilar Hormones Market Trends and Strategies
5. Biosimilar Hormones Market Analysis of End Use Industries
7. Global Biosimilar Hormones Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Biosimilar Hormones Total Addressable Market (TAM) Analysis for the Market
9. Biosimilar Hormones Market Segmentation
10. Biosimilar Hormones Market Regional and Country Analysis
11. Asia-Pacific Biosimilar Hormones Market
12. China Biosimilar Hormones Market
13. India Biosimilar Hormones Market
14. Japan Biosimilar Hormones Market
15. Australia Biosimilar Hormones Market
16. Indonesia Biosimilar Hormones Market
17. South Korea Biosimilar Hormones Market
18. Taiwan Biosimilar Hormones Market
19. South East Asia Biosimilar Hormones Market
20. Western Europe Biosimilar Hormones Market
21. UK Biosimilar Hormones Market
22. Germany Biosimilar Hormones Market
23. France Biosimilar Hormones Market
24. Italy Biosimilar Hormones Market
25. Spain Biosimilar Hormones Market
26. Eastern Europe Biosimilar Hormones Market
27. Russia Biosimilar Hormones Market
28. North America Biosimilar Hormones Market
29. USA Biosimilar Hormones Market
30. Canada Biosimilar Hormones Market
31. South America Biosimilar Hormones Market
32. Brazil Biosimilar Hormones Market
33. Middle East Biosimilar Hormones Market
34. Africa Biosimilar Hormones Market
36. Biosimilar Hormones Market Competitive Landscape and Company Profiles
37. Biosimilar Hormones Market Other Major and Innovative Companies
40. Biosimilar Hormones Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Biosimilar Hormones Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses biosimilar hormones market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for biosimilar hormones? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biosimilar hormones market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Teriparatide Biosimilars; Follitropin Alfa Biosimilars; Insulin Biosimilars; Somatropin Biosimilars; Other Types2) By Application: Research & Biotechnology; Therapeutics; Other Applications
3) By Distribution Channel: Hospital And Retail Pharmacy; Online Pharmacy/pharmacy; Specialty Clinics
Subsegments:
1) By Teriparatide Biosimilars: Osteoporosis Treatment; Bone Health Maintenance2) By Follitropin Alfa Biosimilars: Infertility Treatment; Assisted Reproductive Technology (ART)
3) By Insulin Biosimilars: Type 1 Diabetes Management; Type 2 Diabetes Management
4) By Somatropin Biosimilars: Growth Hormone Deficiency Treatment; Pediatric Growth Disorders
5) By Other Types: Thyroid Hormones; Corticosteroids
Companies Mentioned: Teva Pharmaceutical Industries Ltd.; Gedeon Richter Plc.; Intas Pharmaceuticals Ltd.; Biocon Limited; Mylan; Sanofi; Sandoz Group AG; LG Life Sciences; Ferring Pharmaceuticals; GC Pharma; Pfizer Inc.; Dr. Reddy's Laboratories; Amgen Inc.; Eli Lilly and Company; Celltrion Inc.; Samsungbioepis Co.Ltd; Merck & Co.; Biogen Inc.; Boehringer Ingelheim; Alvotech; Cipla Limited; Lupin Ltd.; Stada Arzneimittel AG; Torrent Pharmaceuticals; Zydus Cadila; Accord Healthcare; Hetero Drugs; Wockhardt
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Biosimilar Hormones market report include:- Teva Pharmaceutical Industries Ltd.
- Gedeon Richter Plc.
- Intas Pharmaceuticals Ltd.
- Biocon Limited
- Mylan
- Sanofi
- Sandoz Group AG
- LG Life Sciences
- Ferring Pharmaceuticals
- GC Pharma
- Pfizer Inc.
- Dr. Reddy's Laboratories
- Amgen Inc.
- Eli Lilly and Company
- Celltrion Inc.
- Samsungbioepis Co.Ltd
- Merck & Co.
- Biogen Inc.
- Boehringer Ingelheim
- Alvotech
- Cipla Limited
- Lupin Ltd.
- Stada Arzneimittel AG
- Torrent Pharmaceuticals
- Zydus Cadila
- Accord Healthcare
- Hetero Drugs
- Wockhardt
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 7.68 Billion |
| Forecasted Market Value ( USD | $ 18.12 Billion |
| Compound Annual Growth Rate | 23.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
